[go: up one dir, main page]

PE20060291A1 - POSACONAZOLE INJECTABLE PHARMACEUTICAL COMPOSITIONS WITH STABILIZED PARTICLES - Google Patents

POSACONAZOLE INJECTABLE PHARMACEUTICAL COMPOSITIONS WITH STABILIZED PARTICLES

Info

Publication number
PE20060291A1
PE20060291A1 PE2005000599A PE2005000599A PE20060291A1 PE 20060291 A1 PE20060291 A1 PE 20060291A1 PE 2005000599 A PE2005000599 A PE 2005000599A PE 2005000599 A PE2005000599 A PE 2005000599A PE 20060291 A1 PE20060291 A1 PE 20060291A1
Authority
PE
Peru
Prior art keywords
posaconazole
microns
particles
infections
moldes
Prior art date
Application number
PE2005000599A
Other languages
Spanish (es)
Inventor
Sydney Ugwu
Varda Sandweiss
Catherine Hardalo
Leonore Witchey-Lakshmanan
Zaiqi Wang
Marco Taglietti
Gopal Krishna
Roberta S Hare
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060291(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20060291A1 publication Critical patent/PE20060291A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UNA FORMULACION INYECTABLE ESTERILIZADA POR AUTOCLAVE, QUE COMPRENDE UNA SUSPENSION ACUOSA DE POSACONAZOL, ESTABILIZADA POR UN FOSFOLIPIDO, EN UNA MEZCLA QUE CONTIENE UN PROTECTOR TERMICO Y UN SISTEMA TAMPON. EL SISTEMA TAMPON CONTIENE UN TAMPON ORGANICO TAL COMO HISTIDINA, ACIDO CITRICO, GLICINA, CITRATO DE SODIO, ENTRE OTROS, EL CUAL PERMITE MANTENER UN PH DE ENTRE 3 A 9; EL FOSOFOLIPIDO PUEDE SER NATURAL Y/O SINTETICO TAL COMO 1-PALMITOIL-2-OLEOIL-SN-GLICERO-3-FOSFOCOLINA (POPC); Y EL PROTECTOR TERMICO CONTIENE TREHALOSA. EL POSACONAZOL TIENE UNA DISTRIBUCION GRANULOMETRICA CUYA MEDIANA ESTA ENTRE 1,0 Y 8,0 MICRONES, CON NO MAS DE 3000 PARTICULAS DE 10 MICRONES O DE MAYOR TAMANO, NI MAS DE 300 PARTICULAS DE 25 MICRONES O DE MAYOR TAMANO. DICHA FORMULACION ES UTIL EN EL TRATAMIENTO DE INFECCIONES TALES COMO CANDIDIASIS OROFARINGEA O ESOFAGICA, ASPERGILOSIS INVASIVA, INFECCIONES CAUSADAS POR HONGOS DIMORFICOS, ZIGOMICOSIS E INFECCIONES INVASIVAS DEBIDAS A MOHOS Y LEVADURAS POCO FRECUENTES, ENFERMEDAD DE CHAGAS Y LEISHMANIASIS, ENTRE OTRASREFERRED TO AN INJECTABLE FORMULATION STERILIZED BY AUTOCLAVE, INCLUDING AN AQUEOUS SUSPENSION OF POSACONAZOLE, STABILIZED BY A PHOSPHOLIPID, IN A MIXTURE CONTAINING A THERMAL PROTECTOR AND A BUFFER SYSTEM. THE BUFFER SYSTEM CONTAINS AN ORGANIC BUFFER SUCH AS HISTIDINE, CITRIC ACID, GLYCINE, SODIUM CITRATE, AMONG OTHERS, WHICH ALLOWS TO MAINTAIN A PH OF BETWEEN 3 TO 9; THE PHOSOPHOLIPID MAY BE NATURAL AND / OR SYNTHETIC SUCH AS 1-PALMITOIL-2-OLEOIL-SN-GLYCERO-3-PHOSPHOCOLINE (POPC); AND THE THERMAL PROTECTOR CONTAINS TREHALOSE. POSACONAZOLE HAS A MEDIUM GRANULOMETRIC DISTRIBUTION WHICH IS BETWEEN 1.0 AND 8.0 MICRONS, WITH NO MORE THAN 3000 PARTICLES OF 10 MICRONS OR LARGER SIZE, NOR MORE THAN 300 PARTICLES OF 25 MICRONS OR LARGER SIZE. SUCH FORMULATION IS USEFUL IN THE TREATMENT OF INFECTIONS SUCH AS OROPHARYNGEAL OR ESOPHAGEAL CANDIDIASIS, INVASIVE ASPERGILLOSIS, INFECTIONS CAUSED BY DIMORPHIC FUNGI, ZYGOMYCOSIS AND INVASIVE INFECTIONS DUE TO MOLDES AND FRESH LEAVES, MOLDES AND LEAVES OF CHEMISTRY

PE2005000599A 2004-05-28 2005-05-27 POSACONAZOLE INJECTABLE PHARMACEUTICAL COMPOSITIONS WITH STABILIZED PARTICLES PE20060291A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57512604P 2004-05-28 2004-05-28

Publications (1)

Publication Number Publication Date
PE20060291A1 true PE20060291A1 (en) 2006-04-14

Family

ID=34971355

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000599A PE20060291A1 (en) 2004-05-28 2005-05-27 POSACONAZOLE INJECTABLE PHARMACEUTICAL COMPOSITIONS WITH STABILIZED PARTICLES

Country Status (15)

Country Link
EP (1) EP1761247A1 (en)
JP (1) JP2008501034A (en)
KR (1) KR20070027564A (en)
CN (1) CN1988887A (en)
AR (1) AR049063A1 (en)
AU (1) AU2005249502A1 (en)
CA (1) CA2567803A1 (en)
IL (1) IL179627A0 (en)
MX (1) MXPA06013886A (en)
NO (1) NO20066005L (en)
PE (1) PE20060291A1 (en)
RU (1) RU2006146555A (en)
TW (1) TWI290051B (en)
WO (1) WO2005117831A1 (en)
ZA (1) ZA200609890B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060009469A1 (en) * 2004-05-28 2006-01-12 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmacutical compositions of posaconazole
RU2008148977A (en) 2006-05-12 2010-06-20 Фармакон-Форшунг Унд Бератунг Гмбх (At) APPLICATION OF COMBINED DRUGS CONTAINING ANTIFUNGIC AGENTS
EP2130540A1 (en) * 2008-06-02 2009-12-09 Sandoz AG Pharmaceutical compositions containing a crystalline form of posaconazole
EP2141159A1 (en) 2008-07-03 2010-01-06 Sandoz AG A Crystalline form of posaconazole
WO2011003992A1 (en) 2009-07-09 2011-01-13 Sandoz Ag A crystalline form of posaconazole
WO2011144655A1 (en) 2010-05-19 2011-11-24 Sandoz Ag Process for the preparation of chiral hydrazides
AU2011254657B2 (en) 2010-05-19 2016-02-04 Sandoz Ag Preparation of posaconazole intermediates
AU2011254658B2 (en) 2010-05-19 2016-02-18 Sandoz Ag Purification of posaconazole and of posaconazole intermediates
MX342850B (en) 2010-05-19 2016-10-14 Sandoz Ag Process for the preparation of chiral triazolones.
MX338685B (en) * 2010-06-29 2016-04-26 Merck Sharp & Dohme Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin.
US9493428B2 (en) 2011-06-16 2016-11-15 Sandoz Ag Process for the preparation of a chiral compound
CN103284959B (en) * 2012-02-22 2015-06-03 重庆圣华曦药业股份有限公司 Posaconazole freeze-dried powder injection and preparation method thereof
CN102755628B (en) * 2012-07-16 2013-10-23 中国科学院微生物研究所 Antifungal pharmaceutical composition
CN102805731B (en) * 2012-08-22 2014-04-30 北京莱瑞森医药科技有限公司 Posaconazole dry suspension and preparation method thereof
CN105030668B (en) * 2015-06-26 2018-03-27 济川药业集团有限公司 Oral posaconazole supensoid agent and preparation method thereof
CN106333925B (en) * 2015-07-10 2019-06-18 上海美悦生物科技发展有限公司 A kind of posaconazole liquid suspension and preparation method thereof
CN105997872B (en) * 2016-07-08 2019-02-19 河南省立眼科医院 An ophthalmic nanomicelle antifungal solution containing posaconazole
CA3056919A1 (en) * 2017-03-26 2018-10-04 Vivi Robyn Stafford Method of treatment of skin conditions of eye lids
EP3609329A4 (en) * 2017-04-12 2021-03-17 Bhagwandin, Vikash J. Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors
CN110507609B (en) * 2018-05-21 2021-09-17 上海医药工业研究院 Preparation method of posaconazole oral suspension
CN111514146A (en) * 2020-04-28 2020-08-11 山西振东泰盛制药有限公司 Pharmaceutical composition containing posaconazole
CN113933131B (en) * 2021-09-24 2024-01-26 合肥天一生物技术研究所有限责任公司 Vaginal microorganism fluorescent staining solution

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
AU2002257104B2 (en) * 2001-04-03 2006-02-09 Merck Sharp & Dohme Corp. Antifungal composition with enhanced bioavailability

Also Published As

Publication number Publication date
CA2567803A1 (en) 2005-12-15
MXPA06013886A (en) 2007-01-26
JP2008501034A (en) 2008-01-17
AU2005249502A1 (en) 2005-12-15
IL179627A0 (en) 2007-05-15
KR20070027564A (en) 2007-03-09
AR049063A1 (en) 2006-06-21
TWI290051B (en) 2007-11-21
RU2006146555A (en) 2008-07-20
NO20066005L (en) 2007-02-27
EP1761247A1 (en) 2007-03-14
CN1988887A (en) 2007-06-27
TW200609001A (en) 2006-03-16
WO2005117831A1 (en) 2005-12-15
ZA200609890B (en) 2008-09-25

Similar Documents

Publication Publication Date Title
PE20060291A1 (en) POSACONAZOLE INJECTABLE PHARMACEUTICAL COMPOSITIONS WITH STABILIZED PARTICLES
PE20130589A1 (en) COMPOSITIONS AND METHODS FOR SUPPLYING THE CENTRAL NERVOUS SYSTEM OF ARYLSULFATASE A
EA200901003A1 (en) FOAMING COMPOSITION FOR DESTRUCTION OF MEMBERS AND ITS APPLICATIONS
AR092470A1 (en) ADALIMUMAB STABLE WATERPROOF FORMULATIONS
CL2015001981A1 (en) (divisional application 1567-2013) combinations of active ingredients comprising pyridylethylbenzamides and other active ingredients
RU2011137204A (en) ANTISEPTIC COMPOSITIONS AND THEIR APPLICATIONS
NI201900090A (en) PHARMACEUTICAL COMPOSITION INCLUDING SELEXIPAG
EA201492021A1 (en) ANTI-COMPOSITION
AR067011A1 (en) FORMULATIONS OF ANTIBODIES
CO6650381A2 (en) Meso-sized particulate pesticide compositions with enhanced activity
AR081364A1 (en) PHARMACEUTICAL COMPOSITIONS OF PAZOPANIB AND METHODS FOR THEIR DEVELOPMENT
CL2008003762A1 (en) Concentrated composition in aqueous suspension for crop protection, comprising an active compound and as stabilizing agents, a non-ionic dispersant and an anionic dispersant and water; methods for preparing said composition and uses thereof, for the care of crops of interest.
PH12014502778B1 (en) Antibody formulation
AR093218A1 (en) A WATERPROOF COMPOSITION INCLUDING DICAMBA AND A DERIVATIVE CONTROL AGENT
CL2018000033A1 (en) Composition to uncover a blocked nose that has antiviral activity.
PE20070437A1 (en) AQUEOUS FORMULATION hFSH
CL2013001730A1 (en) Insecticidal composition comprising an active substance insecticide and wax; active substance-wax particles; procedure for preparing insecticidal composition; spray liquor; use of insecticidal composition to fight pests and / or to protect surfaces from infestation with pests.
CA2798069A1 (en) Stabilized ophthalmic galactomannan formulations
MX2018014631A (en) Liquid neurotoxin formulation stabilized with tryptophan or tyrosine.
PE20181359A1 (en) CROP CARE AND PROTECTION COMPOSITION
PE20080994A1 (en) ANTIHISTAMINE SYRUP, STORAGE STABLE WITHOUT SUGAR
MX2010011117A (en) Aqueous pharmaceutical formulation.
BR112013028531A2 (en) liquid insecticide composition
EA201391555A1 (en) COMPOSITIONS OF SUSPENSION TYPE FOR LOCAL APPLICATION CONTAINING CYCLIC DEPSYPETPID
PE20061154A1 (en) STABILIZED INJECTABLE PHARMACEUTICAL COMPOSITIONS WITH POSACONAZOLE PARTICULATES

Legal Events

Date Code Title Description
FC Refusal